36 results
Page 2 of 2
6-K
EX-99.1
vjaav3gcdv2r3d wb
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
hv73d j3b216ygsdl7x
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
wgxmt7qvgh9
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
1i8l7r2vvnuagydryq
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
ncavj1is5 i4
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
EX-99.2
o8mkukj
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.3
xqm1e56
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
gqd pxjp9u
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
z7g4mx2laa853t56j8x
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
yrpdqhpmv xtl4
17 May 21
Connect Biopharma Announces First
5:27pm
424B4
mmv09p7dtngisww1
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
gvlp1xwd4 r1
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-1/A
q8srtz
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1
f73nmwn 0a9
26 Feb 21
Registration statement (foreign)
4:56pm
DRS/A
c9rs3vzp3tr5flux gr
26 Jan 21
Draft registration statement (amended)
12:00am
DRS
9mxro 4teu98
17 Dec 20
Draft registration statement
12:00am